HomeCompareTARO vs O

TARO vs O: Dividend Comparison 2026

TARO yields 4.65% · O yields 5.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 O wins by $13.8K in total portfolio value· pulled ahead in Year 3
10 years
TARO
TARO
● Live price
4.65%
Share price
$42.98
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.5K
Annual income
$0.47
Full TARO calculator →
O
Realty Income Corporation
● Live price
5.28%
Share price
$61.15
Annual div
$3.23
5Y div CAGR
15.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.2K
Annual income
$5,102.74
Full O calculator →

Portfolio growth — TARO vs O

📍 O pulled ahead of the other in Year 3

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTAROO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TARO + O cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TARO pays
O pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TARO
Annual income on $10K today (after 15% tax)
$395.58/yr
After 10yr DRIP, annual income (after tax)
$0.40/yr
O
Annual income on $10K today (after 15% tax)
$449.12/yr
After 10yr DRIP, annual income (after tax)
$4,337.33/yr
At 15% tax rate, O beats the other by $4,336.93/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TARO + O for your $10,000?

TARO: 50%O: 50%
100% O50/50100% TARO
Portfolio after 10yr
$27.4K
Annual income
$2,551.61/yr
Blended yield
9.33%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on O right now

TARO
Analyst Ratings
1
Buy
1
Hold
Consensus: Buy
Altman Z
3.5
Piotroski
7/9
O
Analyst Ratings
13
Buy
18
Hold
3
Sell
Consensus: Hold
Price Target
$64.00
+4.7% upside vs current
Range: $60.00 — $69.00
Altman Z
1.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TARO buys
0
O buys
0
No recent congressional trades found for TARO or O in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTAROO
Forward yield4.65%5.28%
Annual dividend / share$2.00$3.23
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%15.1%
Portfolio after 10y$20.5K$34.2K
Annual income after 10y$0.47$5,102.74
Total dividends collected$472.00$20.7K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusBuyHold

Year-by-year: TARO vs O ($10,000, DRIP)

YearTARO PortfolioTARO Income/yrO PortfolioO Income/yrGap
1$10,933$232.69$10,818$608.16+$115.00TARO
2$11,817$118.88$11,787$741.68+$30.00TARO
3← crossover$12,704$60.04$12,946$911.00$242.00O
4$13,624$30.16$14,345$1,127.94$721.00O
5$14,592$15.12$16,056$1,409.05$1.5KO
6$15,621$7.57$18,171$1,777.83$2.5KO
7$16,719$3.78$20,820$2,268.21$4.1KO
8$17,891$1.89$24,188$2,929.90$6.3KO
9$19,144$0.95$28,533$3,837.11$9.4KO
10$20,485$0.47$34,235$5,102.74$13.8KO

TARO vs O: Complete Analysis 2026

TAROStock

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug store chains, food chains, hospitals, mass merchandisers, grocery chains, and other direct purchasers and customers, as well as healthcare institutions and private pharmacies. The company was founded in 1950 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. is a subsidiary of Alkaloida Chemical Company Exclusive Group Ltd.

Full TARO Calculator →

OREIT

Realty Income, The Monthly Dividend Company, is an S&P 500 company dedicated to providing stockholders with dependable monthly income. The company is structured as a REIT, and its monthly dividends are supported by the cash flow from over 6,500 real estate properties owned under long-term lease agreements with our commercial clients. To date, the company has declared 608 consecutive common stock monthly dividends throughout its 52-year operating history and increased the dividend 109 times since Realty Income's public listing in 1994 (NYSE: O). The company is a member of the S&P 500 Dividend Aristocrats index. Additional information about the company can be obtained from the corporate website at www.realtyincome.com.

Full O Calculator →
📬

Get this TARO vs O comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TARO vs SCHDTARO vs JEPITARO vs KOTARO vs MAINTARO vs STAGTARO vs ADCTARO vs NNNTARO vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.